C12N 2770/28122
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/28122 (New viral proteins or individual genes, new structural or functional aspects of) appears on 57 US grants and 42 published applications in this corpus.
Search patents in C12N- Granted patents
- 57
- Published applications
- 42
- Assignees
- 36
- Inventors
- 104
- Latest grant
- 25 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 7 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 5 | 1 |
| 2002 | 6 | 1 |
| 2003 | 2 | 9 |
| 2004 | 3 | 2 |
| 2005 | 1 | 1 |
| 2006 | 3 | 1 |
| 2007 | 1 | 0 |
| 2008 | 1 | 0 |
| 2009 | 1 | 0 |
| 2010 | 1 | 4 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 1 | 2 |
| 2015 | 1 | 0 |
| 2016 | 2 | 2 |
| 2017 | 4 | 3 |
| 2018 | 1 | 2 |
| 2019 | 1 | 2 |
| 2020 | 1 | 0 |
| 2021 | 1 | 3 |
| 2022 | 1 | 1 |
| 2023 | 0 | 2 |
| 2024 | 0 | 1 |
| 2025 | 2 | 1 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Virus-like nanoparticles for oral delivery25 Feb 2025US 12,234,260 B2The Regents of the University of California
- Hepatitis c virus E1/E2 heterodimers and methods of producing same21 Jan 2025US 12,202,859 B2The Governors of the University of Alberta
- Virus-like nanoparticles for oral delivery11 Oct 2022US 11,466,055 B2The Regents of the University of California
- Hepatitis C virus E1/E2 heterodimers and methods of producing same30 Nov 2021US 11,186,615 B2The Governors of the University of Alberta
- Hepatitis E virus ORF2 capsid polypeptides and uses thereof29 Dec 2020US 10,875,896 B2Centre Hospitalier Regional Universitaire De Lille
- Hepatitis e virus-like particles (vlps) derived from consensus sequences10 Sep 2026US 2026/0263379 A1Novo Capsid Technologies LLC
- A Fusion Protein and a Particulate Antigen Containing the Same27 Aug 2026US 2026/0250328 A1Xiamen Innovax Biotech Co., Ltd.
- Virus-like nanocapsid for oral delivery of insulin11 Jun 2026US 2026/0159817 A1The Regents of the University of California
- Hepatitis c virus e1/e2 heterodimers and methods of producing same1 May 2025US 2025/0136643 A1
- 2019-ncov (sars-cov-2) vaccine4 Apr 2024US 2024/0108715 A1Vaxbio Ltd
Most cited
By later US patents
- Synthesis deprotection analysis and purification of RNA and ribozymes56US 5,831,071 ARibozyme Pharmaceuticals, Inc. · 1998
- Synthesis, deprotection, analysis and purification of RNA and ribozymes56US 6,469,158 B1Ribozyme Pharmaceuticals, Inc. · 2002
- Synthesis, deprotection, analysis and purification of RNA and ribozymes50US 6,353,098 B1Ribozyme Pharmaceuticals, Inc. · 2002
- N-phthaloyl-protected 2'-amino-nucleoside phosphoramdites46US 5,631,360 ARibozyme Pharmaceuticals, Inc. · 1997
- Hepatitis delta viral polypeptides18US 5,378,814 AChiron Corporation · 1995